0
Signin
countryflagCA

888-969-2592

RY 174.39 2.4016% SHOP 149.115 2.5974% TD-PFM 24.63 -0.0811% TD-PFL 24.7 0.2028% TD 78.325 0.1214% ENB 60.6 1.3039% BN 80.4 1.9787% TRI 226.27 0.7525% CNQ 48.285 2.2771% CP 104.53 1.6038% CNR 151.74 1.5459% BMO 132.69 0.9203% BNS 78.845 0.1715% CSU 4600.2002 2.157% CM 91.15 0.474% MFC 45.79 1.6878% ATD 78.38 1.5285% NGT 60.14 0.0499% TRP 70.15 1.977% SU 57.44 0.5954%

LSL Pharma Group Inc.

Healthcare CA LSL

0.44CAD
0.04(8.64%)

Last update at 2024-11-21T19:10:00Z

Day Range

0.410.44
LowHigh

52 Week Range

0.350.55
LowHigh

Fundamentals

  • Previous Close 0.41
  • Market Cap56.03M
  • Volume18100
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA0.01M
  • Revenue TTM14.32M
  • Revenue Per Share TTM0.16
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.04

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -8.47200M -8.06200M -1.62946M 0.08M
Minority interest - - - -
Net income -8.47200M -8.06200M -1.77692M 0.09M
Selling general administrative 5.39M 3.83M 2.59M 0.61M
Selling and marketing expenses - - - -
Gross profit 1.65M -2.17200M 2.53M 0.51M
Reconciled depreciation 1.13M 1.05M 0.97M 0.37M
Ebit - - - -
Ebitda - - - -
Depreciation and amortization - - - -
Non operating income net other - - - -
Operating income -3.95400M -6.75700M -0.06527M 0.81M
Other operating expenses - - - -
Interest expense 1.57M 1.27M 1.59M 0.53M
Tax provision - - 0.15M -0.00538M
Interest income - - 0.00000M 0.01000M
Net interest income -1.75600M -1.38600M -1.70552M -0.72664M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense - - - -
Total revenue 10.03M 8.21M 8.77M 4.82M
Total operating expenses 13.98M 14.97M 8.84M 4.01M
Cost of revenue 8.38M 10.39M 6.25M 4.32M
Total other income expense net -2.76200M 0.08M 0.14M -
Discontinued operations - - - -
Net income from continuing ops -8.47200M -8.06200M -1.77692M 0.09M
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 30.90M 27.31M 29.03M 23.79M
Intangible assets 8.93M - 9.39M 9.91M
Earning assets - - - -
Other current assets - - - -
Total liab 22.25M 22.02M 17.92M 16.31M
Total stockholder equity 8.65M 5.29M 11.11M 7.48M
Deferred long term liab - - - -
Other current liab - 1.04M 1.46M 1.18M
Common stock - - - -
Capital stock 24.20M 15.05M 12.81M 7.56M
Retained earnings -18.23400M -9.76200M -1.69949M -0.07504M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 0.00800M 0.00000M 0.74M 0.46M
Cash and equivalents - - - -
Total current liabilities 15.07M 11.62M 7.25M 11.81M
Current deferred revenue - - - -
Net debt 13.71M 12.16M 9.13M 8.87M
Short term debt - - - -
Short long term debt 8.98M 4.31M 1.89M 5.83M
Short long term debt total - - - -
Other stockholder equity - - - -
Property plant equipment - - - -
Total current assets 7.20M 4.39M 6.48M 3.92M
Long term investments - - - -
Net tangible assets - - - -
Short term investments - - - -
Net receivables 2.55M 0.96M 1.12M 1.55M
Long term debt 4.73M 7.84M 7.98M 3.51M
Inventory 4.11M 2.96M 4.17M 1.64M
Accounts payable 4.92M 4.54M 2.54M 2.47M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - - -
Deferred long term asset charges - - - -
Non current assets total 23.70M 22.92M 22.55M 19.87M
Capital lease obligations 2.56M 2.70M 2.87M 1.23M
Long term debt total - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -1.01700M -0.99700M -1.03969M -1.19384M
Change to liabilities - - - -
Total cashflows from investing activities - - - -
Net borrowings - - - -
Total cash from financing activities 8.10M 3.42M 0.94M 1.74M
Change to operating activities - - - -
Net income -8.47200M -8.06224M -1.77692M 0.09M
Change in cash 0.00800M -0.74100M -1.18448M 0.43M
Begin period cash flow 0.00000M 0.74M 1.93M 0.03M
End period cash flow 0.00800M 0.00000M 0.74M 0.46M
Total cash from operating activities -7.07000M -3.16400M -1.08495M -0.11785M
Issuance of capital stock 9.46M 2.37M 2.65M 3.23M
Depreciation 1.13M 1.05M 0.97M 0.37M
Other cashflows from investing activities - - - -
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory - - -2.03655M -0.38346M
Change to account receivables - - 0.96M -0.36354M
Sale purchase of stock - - - -
Other cashflows from financing activities - - - -
Change to netincome - - - -
Capital expenditures 1.02M 1.00M 0.91M 0.09M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -4.74000M 2.97M -1.99368M -0.38465M
Stock based compensation 2.12M 0.00000M - -
Other non cash items 2.90M 0.88M 1.56M -0.18885M
Free cash flow -8.08700M -4.16100M -1.99974M -0.20335M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LSL
LSL Pharma Group Inc.		 0.04 8.64% 0.44 - - 3.91 2.88 4.85 636.87
RX
Biosyent Inc.		 -0.05 0.44% 11.25 18.58 15.70 3.82 3.65 3.34 11.28
LOVE
Cannara Biotech Inc		 0.01 1.49% 0.68 11.00 - 0.77 0.73 1.34 6.59
ZYUS
ZYUS Life Sciences Corporation		 0.10 13.33% 0.85 - - 135.51 3.73 157.30 -4.258
SBBC
Simply Better Brands Corp		 0.02 2.44% 0.84 - 14.14 0.67 1.18 0.51 -5.4938

Reports Covered

Stock Research & News

View All

Profile

LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical and natural health products in Canada. It offers dietary supplements and vitamins in the tablet and capsule form; and niche sterile ophthalmic products in the form of ointments and drops for pharmacy banners and hospitals. The company is headquartered in Boucherville, Canada.

LSL Pharma Group Inc.

540, d?Avaugour Street, Boucherville, QC, Canada, J4B 0G6

Key Executives

Name Title Year Born
Mr. Francois Roberge Chairman, President & CEO 1965
Marc Boudreault Vice-President of Communications NA
Ms. Mélanie St-Pierre CFA Corporate Controller NA
Mr. Luc Mainville M.B.A, M.B.A. CFO & Director 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.